Compass Therapeutics, Inc. Common Stock (CMPX) Stock
NASDAQ · CMPX
Key stats
- Market cap
- $161.48M
- Price / Earnings ratio
- -2.2x
- EPS (TTM)
- -$0.39
- Volume
- Loading
- 52-week high
- $6.88
- 52-week low
- $0.82
Source: third-party data provider, as of October 17, 2026
Compare with CMPX
Recent news

Stocktwits
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside
CMPXSeptember 22, 2026
Stocktwits
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside
CMPX

MarketBeat
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
CMPXJune 8, 2026
MarketBeat
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
CMPX

The Motley Fool
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
CMPXMarch 2, 2026
The Motley Fool
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
CMPX

Zacks Investment Research
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?
CMPXFebruary 17, 2026
Zacks Investment Research
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?
CMPX
Technical indicators
- RSI 14
- 25.98
- MACD 12/26/9
- -0.26
- EMA 9 of MACD
- -0.28
- MACD histogram
- 0.02
- SMA 50
- $1.79
- Price below SMA 50
- EMA 50
- $1.58
- Price below EMA 50
- SMA 200
- $3.44
- Price below SMA 200
- EMA 200
- $3.20
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Strong Sell0
Sell0
Hold1
Buy5
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
264M174M87M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-66.5M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Stocktwits
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside
CMPXSeptember 22, 2026
Stocktwits
CMPX Plunge Wipes Out $104M After FDA Demands Fresh Trial For Cancer Drug — Wedbush Sees Another 19% Downside
CMPX

MarketBeat
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
CMPXJune 8, 2026
MarketBeat
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
CMPX

The Motley Fool
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
CMPXMarch 2, 2026
The Motley Fool
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
CMPX

Zacks Investment Research
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?
CMPXFebruary 17, 2026
Zacks Investment Research
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?
CMPX

Zacks Investment Research
Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High?
CMPXJanuary 27, 2026
Zacks Investment Research
Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High?
CMPX

Zacks Investment Research
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year?
CMPXDecember 19, 2025
Zacks Investment Research
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year?
CMPX

Zacks Investment Research
Wall Street Analysts Think Compass Therapeutics, Inc. (CMPX) Could Surge 134.14%: Read This Before Placing a Bet
CMPXDecember 12, 2025
Zacks Investment Research
Wall Street Analysts Think Compass Therapeutics, Inc. (CMPX) Could Surge 134.14%: Read This Before Placing a Bet
CMPX

Zacks Investment Research
Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy
CMPXDecember 8, 2025
Zacks Investment Research
Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy
CMPX

Zacks Investment Research
2025's Top 3 Breakout Stocks for Active Traders: Don't Miss Out!
CMPXNovember 20, 2025
Zacks Investment Research
2025's Top 3 Breakout Stocks for Active Traders: Don't Miss Out!
CMPX

InvestorPlace
3 Penny Stocks With the Power to 10X Your $1K Investment
CMPXMarch 24, 2024
InvestorPlace
3 Penny Stocks With the Power to 10X Your $1K Investment
CMPX
About Compass Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees39
CEODr. Thomas J. Schuetz M.D., Ph.D.
IPO DateApr 5, 2021
HeadquartersBoston, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Thomas J. Schuetz M.D., Ph.D. | CEO & Vice Chairman | 1961 |
| Mr. Barry Shin J.D., M.B.A. | Chief Financial Officer | 1972 |
| Mr. Jonathan E. Anderman J.D. | Senior VP, General Counsel & Corporate Secretary | 1983 |
| Mr. Neil L. Lerner CPA | Senior VP & Chief Accounting Officer | 1967 |
| Mr. Bing Gong Ph.D. | Chief Scientific Officer | 1976 |
| Anna Gifford | Senior Manager of Communications & Chief of Staff | — |
| Ms. Karin Herrera B.A. | Senior VP & Head of Clinical Operations | — |
| Dr. James Kranz Ph.D. | VP and Head of Chemistry Manufacturing & Controls | — |
| Dr. Cynthia A. Sirard M.D., Ph.D. | Chief Medical Officer | 1970 |
| Mr. Arjun Prasad M.B.A., M.P.H. | Chief Commercial Officer | 1978 |
Fundamentals
Valuation
Price-to-book value0.95
Profitability
Return on Equity-39.00%
Return on Assets-35.00%
EBITDA$-71.96M
Trading
Average volume7,039,998
Source: third-party data provider, as of October 17, 2026
Technical indicators
- RSI 14
- 25.98
- MACD 12/26/9
- -0.26
- EMA 9 of MACD
- -0.28
- MACD histogram
- 0.02
- SMA 50
- $1.79
- Price below SMA 50
- EMA 50
- $1.58
- Price below EMA 50
- SMA 200
- $3.44
- Price below SMA 200
- EMA 200
- $3.20
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 15, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
83% Buy
17% Hold
0% Sell
Analyst price target
- Low
- $1.00
- Average
- $5.83
- High
- $12.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -20.4 | -11.7 | ||||||||||
| 2022 | -50.0 | +20.8 | -31.8 | +0.0 | +108.9 | -9.2 | -1.9 | +4.2 | -21.4 | +23.9 | +20.2 | +9.3 |
| 2023 | -22.3 | -5.0 | -12.3 | -5.9 | -7.1 | +7.4 | -8.0 | -13.1 | -17.2 | -6.7 | -6.8 | -7.7 |
| 2024 | -12.2 | +42.4 | +4.2 | -21.7 | -10.2 | -26.5 | +8.4 | +58.0 | +21.9 | -13.7 | -4.1 | -12.7 |
| 2025 | +130.0 | -5.8 | -30.4 | -17.0 | +15.4 | +20.9 | +15.1 | +18.3 | +2.0 | +11.3 | +55.1 | -1.6 |
| 2026 | +23.8 | -13.3 | -6.9 | -67.4 | +21.4 | -1.4 | -12.4 | +26.5 | -55.0 | +0.0 |
Compare stocks
Market cap
$161.48M
-
-
-
Price / Earnings ratio
-2.20
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
7,039,998
-
-
-
Earnings per share
$-0.39
-
-
-



